Cargando…
The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase
T-705 (Favipiravir) is a broad-spectrum antiviral molecule currently in late stage clinical development for the treatment of influenza virus infection. Although it is believed that T-705 potency is mediated by its ribofuranosyl triphosphate (T-705 RTP) metabolite that could be mutagenic, the exact m...
Autores principales: | Jin, Zhinan, Smith, Lucas K., Rajwanshi, Vivek K., Kim, Baek, Deval, Jerome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707847/ https://www.ncbi.nlm.nih.gov/pubmed/23874596 http://dx.doi.org/10.1371/journal.pone.0068347 |
Ejemplares similares
-
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2
por: Pertinez, Henry, et al.
Publicado: (2021) -
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
por: FURUTA, Yousuke, et al.
Publicado: (2017) -
Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis
por: Yamada, Kentaro, et al.
Publicado: (2016) -
Favipiravir (T-705) protects against Nipah virus infection in the hamster model
por: Dawes, Brian E., et al.
Publicado: (2018) -
Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
por: Srinivasan, Kritika, et al.
Publicado: (2021)